All PlansCoverageMedium impact
Gene Expression Profiling, Protein Biomarkers, and Multimodal Artificial Intelligence for Prostate Cancer Management
Blue Cross & Blue Shield of Mississippi·MS · Urology, Oncology·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a comprehensive policy establishing coverage criteria for gene expression profiling, protein biomarkers, and AI-based tests for prostate cancer management. The policy covers various testing scenarios including risk stratification for newly diagnosed patients, post-prostatectomy monitoring, and treatment selection for advanced disease.
Action Required
Review policy document for specific coverage criteria and prior authorization requirements for prostate cancer genetic and biomarker testing. Billing team should identify which specific tests (Prolaris, Oncotype Dx Prostate, Decipher, ProMark, Artera Prostate Test) are ordered by providers and verify coverage requirements before billing.